報價延遲最少15分鐘:2025/01/11 17:17 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.4391 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.88/--
|
|
企業價值
68.63M
|
| 資產負債 |
|
每股賬面淨值
1.05
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 17:17 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies. |